Sample size determination in fixed-dose combination drug studies

被引：4
|
作者：
Sidik, K
Jonkman, JN
机构：
[1] Wyeth Res, Biometr Res, Princeton, NJ 08543 USA
[2] Mississippi State Univ, Dept Math & Stat, Mississippi State, MS 39762 USA
来源：
PHARMACEUTICAL STATISTICS | 2003年 / 2卷 / 04期
关键词：
binary response; combination drug; intersection-union test; min test;
D O I：
10.1002/pst.67
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
In this paper, the application of the intersection-union test method in fixed-dose combination drug studies is discussed. An approximate sample size formula for the problem of testing the efficacy of a combination drug using intersection-union tests is proposed. The sample sizes obtained from the formula are found to be reasonably accurate in terms of attaining the target power 1 - beta for a specified beta. Copyright (C) 2003 John Wiley Sons Ltd.
引用
收藏
页码：273 / 278
页数：6
相关论文
共 50 条
  • [21] Fixed-Dose Combination Therapy in HypertensionPros
    Stefano Taddei
    High Blood Pressure & Cardiovascular Prevention, 2012, 19 (2) : 55 - 57
  • [22] Fixed-dose combination lercanidipine/enalapril
    Hair P.I.
    Scott L.J.
    Perry C.M.
    Drugs, 2007, 67 (1) : 95 - 106
  • [23] Compliance and fixed-dose combination therapy
    Sripal Bangalore
    Anupama Shahane
    Sanobar Parkar
    Franz H. Messerli
    Current Hypertension Reports, 2007, 9 : 184 - 189
  • [24] Fixed-dose combination antihypertensive medications
    Benjamin, Ivor J.
    Kreutz, Reinhold
    Olsen, Michael H.
    Schutte, Aletta E.
    Lopez-Jaramillo, Patricio
    Frieden, Thomas R.
    Sliwa, Karen
    Lackland, Daniel T.
    Brainin, Michael
    LANCET, 2019, 394 (10199): : 637 - 638
  • [25] Fixed-Dose Combination Therapy for Psoriasis
    Lyn C. Guenther
    American Journal of Clinical Dermatology, 2004, 5 : 71 - 77
  • [26] Fixed-Dose Combination Therapy in HypertensionCons
    Fabio Angeli
    Gianpaolo Reboldi
    Giovanni Mazzotta
    Marta Garofoli
    Elisa Ramundo
    Cristina Poltronieri
    Paolo Verdecchia
    High Blood Pressure & Cardiovascular Prevention, 2012, 19 (2) : 51 - 54
  • [27] Compliance and fixed-dose combination therapy
    Bangalore, Sripal
    Shahane, Anupama
    Parkar, Sanobar
    Messerli, Franz H.
    CURRENT HYPERTENSION REPORTS, 2007, 9 (03) : 184 - 189
  • [28] Bioequivalence of fixed-dose combination RIN®-150 to each reference drug in loose combination
    Wang, H. F.
    Wang, R.
    O'Gorman, M.
    Crownover, P.
    Damle, B.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2015, 19 (03) : 333 - 338
  • [29] Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
    Fuwa, Masahiro
    Ueda, Kenji
    Akaishi, Takahiro
    Yamashita, Naoko
    Kirihara, Tomoko
    Shimazaki, Atsushi
    Mano, Hidetoshi
    Kawazu, Kouichi
    PLOS ONE, 2016, 11 (07):
  • [30] Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir
    Polina German
    Anita Mathias
    Diana M. Brainard
    Brian P. Kearney
    Clinical Pharmacokinetics, 2018, 57 : 1369 - 1383
12345